For the treatment of bacterial infections in animals.
INDICATIONS FOR ADMINISTRATION OF DORYNUM.
For therapeutic purpose to the animals under 9 months of age having:
respiratory and other diseases of bacterial etiology, the pathogens of which are sensitive to doxycycline and rifampicin.
Ready 3% solution of rifampicin and doxycycline 10 ml and 100 ml.
rifampicin Rec.INN registered by WHO;
doxycycline Rec.INN registered by WHO.
1.2. 100 cm3 of the drug contains doxycycline (in the form of doxycycline hyclate) - 1.5 g; rifampicin - 1.5 g; auxiliary components - water for injection - up to 100 m3.
1.3. Appearance: red-brown odorless liquid, not volatile.
1.4. Dorynum-R is produced packaged in 10 cm3, 20 cm3, 30 cm3, 50 cm3, 100 cm3 glass vials of the appropriate volume, hermetically sealed with rubber stoppers and reinforced with aluminum caps. The vials are placed in cardboard boxes and supplied with instructions for use.
1.5. The drug should be stored in the manufacturer’s sealed packaging in a dry place protected from direct sunlight, separate from food and feed, out of reach of children, at temperatures from + 2 °C to + 10 °C. Shelf life with the storage conditions observed is 1 year from the date of manufacture.
Standard therapeutic use of one vial is intended for 60 and 600 kg of live weight; does not require dilution.
2.1. Dorynum-R is a complex antibacterial drug. The antibacterial mechanism of doxycycline is based on inhibition of protein synthesis in bacteria at the ribosomal level. Rifampicin blocks RNA synthesis in a bacterial cell by inhibiting DNA-dependent RNA polymerase. The synergistic effects of rifampicin and doxycycline lead to the death of most gram-positive and gram-negative microorganisms, including escherichia, salmonella, pasteurella, staphylococcus, streptococcus, pneumococcus, meningococcus, brucella, bordetella, clostridia, listeria, rickettsia, chlamydia and mycoplasma.
2.2. After administration of the drug, the components are well absorbed into the blood and penetrate into all organs and tissues. The peak serum concentration is achieved 1-2 hours after administration and persists at the therapeutic level for 24 hours. The drug is eliminated from the body mainly with feces and partially with urine.
2.3. Dorynum-R by its degree of exposure to the body belongs to moderately hazardous substances (hazard class 3 according to GOST 12.1.007).
3.1. Dorynum-R is prescribed for medicinal purposes to young cattle and piglets with colibacteriosis, salmonellosis, respiratory and other diseases of bacterial etiology, the pathogens of which are sensitive to the drug.
3.2. Dorynum-R is used in animals at a dosage of 1.7-3.5 ml per 10 kg of mass intramuscularly once a day, for 3-7 days.
If necessary, a repeat of the treatment course is possible.
3.3. It is forbidden to use the drug in adult animals (cattle), as well as in animals with increased individual sensitivity to the components of the drug.
3.4 As a rule, there are no side effects and complications when using the drug in accordance with this instruction. If allergic reactions occur, the use of Dorynum-R must be discontinued and desensitizing therapy is to be performed.
3.5. No specific features of the action during the first administration of the drug and during its withdrawal have been established. Missing the doses of the drug should be avoided, as this can lead to a decrease in therapeutic effectiveness. In case of missing one or more doses of the drug, the course of use must be resumed in prescribed dosage and scheme.
3.6. It is forbidden to use Dorynum-R simultaneously with medications containing aluminum, calcium, magnesium and iron salts, due to formation of difficultly soluble complexes.
3.7. Slaughter of animals for food purposes during the period of treatment with the drug is prohibited. Meat is allowed for consumption 15 days after the last application. In the case of forced slaughter before the waiting period expires, animal meat can be used to feed carnivores.
4.1. When working with the drug, the general rules of personal hygiene and safety precautions provided for working with veterinary medications should be observed.
5.1. In the event of complications after the use of the drug, its use should be stopped, and the consumer should contact the local state veterinary institution. Veterinary specialists of this institution shall study compliance with all the rules for the use of the drug in accordance with the instructions. In case of confirmation of the negative effect of the drug on the animal’s body, veterinary specialists shall take necessary quantity of samples (at least 3 unopened packages of the drug from the series that caused the complications) for laboratory tests, write a sampling report and send it to the State Institution “Belarusian State Veterinary Center’’ to confirm drug’s compliance with regulatory documents.
II. PHARMACOLOGICAL PROPERTIES
III. ADMINISTRATION PROCEDURE
IV. PERSONAL PREVENTION MEASURES
V. COMPLAINTS FILING PROCEDURE